EACS2023: 176 Real-life experience on dolutegravir and lamivudine as initial or switch treatment in a silver population living with HIV M. Mazzitelli , S. Gardin , L. Sasset , D. Leoni , M. Trunfio , D. Mengato , V. Scaglione , E. Agostini , E. Vania , A. Cattelan Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, University of Turin, Turin, Italy, Hospital Pharmacy Unit, Padua University Hospital, Padua, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Randomized clinical trials and real-life studies granted efficacy and safety of dolutegravir and lamivudine (DTG/3TC) in naïve and experienced people living with HIV (PLWH), but there are no long-term data in people over 65 years of age. We herein describe our real-life experience (with more than 5 years of follow-up) of PLWH ≥ 65 years of age (PLWH≥65) who started or were switched to DTG/3TC or DTG+3TC. Method: We retrospectively included all PLWH≥65 who ever started or were switched to DTG/3TC or DTG+3TC in our center, retrieving data from medical records. We considered laboratory and clinical parameter changes from the baseline to the last follow-up time point available for each person, and analyzed factors associated with virological failure (VF) and discontinuation. The intra-subject changes were analyzed by paired Wilcoxon test. Results: We included 112 PLWH, median age of 66 (IQR 65-70) years, mostly males (77.6%), 84.4% people had multimorbidity, 34.8% on polypharmacy, only 5.4% were naïve to treatment, 47% PLWH started this combination as 2-pill regimen, and all but 6 were switched to single tablet as soon as it was available. The three reasons to be switched to DTG/3TC were: abacavir removal (37.5%), drug-interactions (20.5%), and treatment simplification (42%). Median treatment durability was 6 (IQR 5.4-7) years. Parameters and score from baseline to follow-up are reported in Table 1 (n=104). We observed 8 discontinuations (2 deceased, 2 VF with no resistance, 2 early intolerances, 1 weight gain, 1 switch to long-acting). No factors were significantly associated with VF or discontinuation. Conclusions: This is the first study on DTG/3TC in PLWH≥ 65 years of age. Even if more data is needed, DTG/3TC resulted to be safe and effective in this population, with no impact on immunological and metabolic parameters, and with low rate of discontinuation due to toxicity or virological failure. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 2 3 1 1 1 1 1 2 3 87
RkJQdWJsaXNoZXIy Mzc2ODc=